Pharmaceutical manufacturers of Praziquantel

Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. In 2000, an A-share was issued in order to enter the stock market as a state-owned listed company. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times. In 2020 Hisun Pharmaceuticals received special recognition from the Joint Prevention and Control Team from the State Council of the People’s Republic of China for their extraordinary efforts in the fight against the epidemic, and Hisun Pharmaceutical was awarded with the “Anti COVID-19 Advanced Collective in Ministry of Industry and Information Technology".

Chromo Labs operates as a fully integrated pharmaceutical company, engaging in international, active pharmaceutical ingredient (API), and oral solid dosage (OSD) manufacturing. With approvals from USFDA, EDQM, WHO GENEVA, COFEPRIS, ANVISA, and EUWC, Chromo API holds 19 CEP approvals and has 7 CEPs under review. Additionally, Chromo API has filed 35 USDMFs, 6 of which are currently commercialized. The company possesses a comprehensive backup API portfolio, supported by Chromo Medcare and Gensynth Pharmachem.

Established in Darmstadt, Germany in 1668 by Friedrich Jacob Merck, Merck KGaA stands as the oldest pharmaceutical and chemical corporation globally. It is renowned for its pioneering and high-quality advanced products in the fields of healthcare, life science, and performance materials. Internationally, the company is recognized as Merck, while operating as EMD Serono in the Biopharma sector, as MilliporeSigma in the Life Science sector, and as EMD Performance Materials in the materials sector in the United States and Canada.

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of Caring for Life and deep-rooted community links wherever it is present, make it a partner of choice for global health bodies and stakeholders.

We are a technology-focused, multi-dimensional pharmaceutical company having state-of-the-art manufacturing capabilities in diverse therapeutic areas such as Cardiology, Diabetology, Pain Management, Dermatology, Ophthalmology, Neurology and more. We strive towards unlocking the power of science to provide access to affordable and innovative medicines to improve health outcomes and make a difference in people's lives across the globe. As we continue to champion the cause of Make-in-India through our steady expansion across various Indian states, we create job opportunities and drive social responsibility programs in education, healthcare, rural development and environmental protection to add value to our local communities. Our roadmap is to continue investing in discovering, developing, manufacturing, and commercializing innovative medicines. Meeting the growth and profitability goals through successful innovation in digital healthcare trends and commercial excellence will continue to be the driving factors over the next decade.

We specialize in premium Active Pharmaceutical Ingredients (APIs), Formulations, Innovative Drug Delivery Systems, and Specialty Chemicals using advanced technology with precision to adhere to global standards/specifications. Presently, we are recognized as one of the foremost global providers of Oncology/non-Oncology APIs, intermediates, and Formulations. Shilpa Medicare’s establishments have garnered significant regulatory endorsements from USFDA, EUGMP, TGA, PMDA, Cofepris, Anvisa, and KFDA, encompassing diverse regulatory approved manufacturing standards.

Our objective is to pave the path to a more wholesome future. However, we are also concerned about the manner in which we collectively achieve this goal. Being a company whose products impact the well-being of individuals worldwide, we uphold ourselves to a stringent standard and anticipate others to treat us likewise. We are advocates of transparent, truthful, and principled operation with the utmost level of ethics and honesty. This encompasses ensuring the company's compliance with all relevant laws and regulations on a global scale.

Solara is an API manufacturer focused on research and customer satisfaction, operating in over 75 countries. They specialize in producing APIs for niche therapeutic categories, including complex products like polymer-based APIs and injectable APIs. The company has a team of experienced scientists supported by 6 manufacturing facilities and 2 R&D centers. Additionally, Solara offers Contract Research and Manufacturing Services (CRAMS) from discovery to late phase commercial manufacturing. Solara Active Pharma Sciences, with roots in Strides Shasun Ltd. and Sequent Scientific Ltd., is committed to providing value-based products while prioritizing customer needs. The company has 140+ scientists working at 2 R&D centers and 4 API manufacturing facilities, all with global approvals and 2 dedicated R&D facilities.

Shanghai Acebright Pharmaceuticals Group Co Ltd was established in 1996. Over 12 manufacturing facilities conforming to GMP standards are situated in China and India. The company specializes in a range of Vitamin products, ARV APIs & intermediates, and oncology APIs & finished pharmaceutical products. It serves as an integrated CDMO service partner from R&D to commercial manufacturing.

Rochem International, Inc. has been a prominent distributor of pharmaceutical, food, nutritional, and animal health ingredients since its establishment in 1994. It procures top-notch ingredients produced in China. With its headquarters in Hauppauge, New York, Rochem operates 16 global offices to meet its clients' requirements. The company's activities adhere to cGMP standards and have undergone audits by the USFDA and various multinational entities. Furthermore, it provides training and conducts audits for its partners to ensure FDA compliance for their technologies and systems.

Bayir is a professionally managed corporation involved in the manufacturing and promotion of specific active Pharmaceuticals, Nutraceutical, and Botanical extracts such as Coleus Forskolin, Glucosamine, Garcinia Extract, Chondroitin sulphate, Herbal Extract, and Curcumin. The manufacturing units of the corporation are furnished with modern facilities operated by highly qualified experts and are WHO cGMP certified.

SeQuent is looking towards the future with courage and confidence, because of the critical role it can play to help make a difference in global economic progress and social wellbeing. Ever since inception in 2002 SeQuent has emerged as an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation) We have branded our Animal Health business as Alivira Animal Health with a singular focus to create value in the global animal health space. We cater to unaddressed global market requirements and focus on products for livestock, poultry and companion animals. Our value proposition includes laboratory and technical support services.

Over the last few years, we have emerged as India’s largest animal health company with presence in 100+ countries. Our logotype is inspired by nature and its different forms and shapes -from a microscopic view of the skin texture to footprint of a chosen animal. The circular shape evokes the idea of protection and control. It’s a closed and perfect shape that is naturally balanced, reminiscing the brand idea “Animals’ Source of Health”. Pronounced A-lee-vee-rah, the name is a variant of two Latin words Elvira, word for ‘white, pure, clean’ and Alleviare, word for ‘relief’. It speaks about our commitment to improving animals’ life and well-being at every stage. We are Alivira! Our focus on R&D is taking us even further, and we are committed to applying cutting-edge resources to improve health and well-being at every stage of animals’ lives. All along our processes, we are committed to quality, but moreover, we are committed to safety. That is our guarantee for effective medicines.

We are the primary manufacturer of Avermectin worldwide and the leading producer of Ivermectin in Asia, with an annual production that constitutes half of the total in China. Additionally, we hold the top position as the producer for Tiamulin, Eprinomectin, and Emamectin Benzoate in China.

Minsheng Group Shaoxing Pharmaceutical Co., Ltd.（herein after called Minsheng), located in Shaoxing city, China. With its extensive expertise and advanced facilities, Minsheng specializes in manufacturing APIs. Minsheng is the subsidiary of Hangzhou Minsheng Pharmaceutical Holding Group Co.,Ltd. which has nearly 100 years history. Covering a total area of 235,000M2, Minsheng has nearly 500 employees. More than 30% of these professionals are specialized technical personnel. Minsheng primarily manufactures over 30 types of APIs, with approximately 50% of the output being exported. Nine products have obtained US FDA approval , two products have acquired EU CEP, one product has received recognition from Japan PMDA, and one product has listed in WHO PQ. Minsheng possesses extensive experience in collaborating with big pharma. Companies. Minsheng pays much attention on regulatory compliance including but not limited to GMP and EHS. Minsheng also focus on R&D new projects, fully support all innovation ideas & execution. Minsheng has a new plant site in a specialized Chemical Park, Shangyu city. Minsheng now is embracing new projects and larger development.

Nanjing Pharmaceutical Factory Co., Ltd. (NPF) was established in 1935. Following this, the organization carried out relocations of its facilities, relocating the finished dosage plant to Nanjing Xingang Industrial Park in 2001 and the API plant to Nanjing Chemical Industrial Park in 2003. Over time, NPF has evolved into a sizable and integrated producer with robust research and development capabilities for API, finished dosage, and pharmaceutical intermediates. The API facility spans 120,000 square meters and comprises 6 specialized and versatile workshops, along with extensive land for potential expansion. Manufacturing and quality systems are operated in compliance with cGMP regulations. Nanjing Well Pharmaceutical Group Co., Ltd. was formed in 2000 through the comprehensive conversion of the original Nanjing Well Chemical Co., Ltd. Since its inception, the firm has concentrated on the research and development, manufacturing, and marketing of pharmaceutical excipients and synthetic lubricating base oils, supplying customers with advanced new products such as high-safety and multifunctional pharmaceutical excipients and synthetic lubricating base oils with outstanding performance. The company's pharmaceutical excipient products are utilized in various pharmaceutical dosage forms, including injections, oral administration, and external applications.

Chengxin Pharmaceutical, also known as CX Pharma, is a cutting-edge professional API firm specializing in bio-enzyme technology and chemical synthesis. Their products are extensively utilized in the pharmaceutical, supplement, and cosmetics sectors. The company boasts a workforce of over 300 employees, with 45% holding master's, PhD, or overseas returnee qualifications. The manufacturing facility adheres to GMP, CGMP, and FDA standards in its design and management. With a focus on green economy, advanced technology, and humane management, the company aims to deliver the highest quality API to its global clientele.